{"id":14869,"date":"2023-04-03T20:18:53","date_gmt":"2023-04-04T00:18:53","guid":{"rendered":"https:\/\/sosv.com\/?p=14869"},"modified":"2023-12-27T19:31:48","modified_gmt":"2023-12-28T00:31:48","slug":"the-2023-sosv-human-health-100","status":"publish","type":"post","link":"https:\/\/sosv.com\/the-2023-sosv-human-health-100\/","title":{"rendered":"The 2023 SOSV Human Health 100"},"content":{"rendered":"
\n
\"\"<\/figure><\/div>\n\n\n

Welcome to the second annual SOSV Human Health 100. The list captures  SOSV\u2019s 100 most exciting companies in human health as of April 2023.<\/p>\n\n\n\n

SOSV\u2019s core mission, which we pursue through our IndieBio<\/a>, HAX<\/a>, and Orbit<\/a> startup development programs, is to fund and foster startups that will improve human and planetary health. In addition to the Human Health 100, each year we also publish our SOSV Climate Tech 100<\/a>. <\/p>\n\n\n\n

Those twin missions – health and climate – aim to better human health today and for generations to come, as well as ensure that earth remains a hospitable human habitat. Even though we live in an era of astonishing technological advances such as CRISPR and mRNA, we are also facing civilization-level threats from disease, pandemics and climate change. At SOSV, we believe it has never been more important to apply the energy and genius of founders to addressing those challenges. That is we do every day in our deep tech startup development programs<\/a>, HAX <\/a>and IndieBio<\/a>, in their well staffed and equipped labs and workshops.<\/p>\n\n\n\n

<\/p>\n\n\n\n

The Numbers<\/strong><\/h2>\n\n\n\n

This year\u2019s SOSV Human Health 100 shows strong growth in both funding and valuations. About 2\/3 of the companies are at the seed stage, 1\/3 at Series A or more, and only 2 have reached  \u2018Growth\u2019 stage (unicorns Opentrons and Formlabs).<\/p>\n\n\n\n

The aggregate valuation of the companies on the list is $6.47 billion<\/strong> (up 14% from $5.65B in 2022), and all told the firms have raised $1.42 billion<\/strong> (up 42% from $1B in 2022). SOSV, which invests starting at pre-seed and continues through later stages, has invested $96 million<\/strong>  (up 32% from $73M in 2022). Investment outpaced valuation gains this year, likely due to the headwinds facing startup valuations. <\/p>\n\n\n\n

This year\u2019s list also welcomes 18 newcomers, who are listed below.  It\u2019s important to stress that year-to-year  individual companies in the SOSV portfolio experience many ups and downs due to new fundings, regulatory breakthroughs and commercial partnerships. Joining or leaving this list is anything but a surefire indicator of future outcomes. (The 2022 list is available here<\/a>. )<\/p>\n\n\n\n

<\/td>Total Valuation<\/mark><\/strong><\/td>Countries<\/mark><\/strong><\/td>Total Raised<\/mark><\/strong><\/td>Female Founders<\/mark><\/strong><\/td>SOSV Funding<\/mark><\/strong><\/td>PhD Founders<\/mark><\/strong><\/td><\/tr>
2022<\/strong><\/td>$5.65B<\/td>19<\/td>$1.0B<\/td>30%<\/td>$73M<\/td>62%<\/td><\/tr>
2023<\/strong><\/td>$6.47B<\/td>17<\/td>$1.42B<\/td>30%<\/td>$96M<\/td>67%<\/td><\/tr>
Change<\/strong><\/td>+14%<\/strong><\/mark><\/td><\/td>+42%<\/strong><\/mark><\/td><\/td>+32%<\/mark><\/strong><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Note: this table is based on actual funding amounts.<\/p>\n\n\n\n

The Founders<\/h2>\n\n\n\n

As with the SOSV Climate Tech 100, the diversity and sophistication of our health companies and founders is striking. Nearly 30%<\/strong> of the companies have a woman co-founder. The companies are located in 17<\/strong> countries; topping the list are the US (59), Canada (9) and the UK (9), followed by France (3). 67%<\/strong> of the startups have at least one PhD co-founder. A  total of 52 companies graduated from the biology-centric IndieBio<\/strong> while another 38 hail from hard-tech focused HAX<\/strong>, and five hail  from the Orbit<\/strong> program.<\/p>\n\n\n\n

SOSV expands its health portfolio by accepting dozens of pre-seed health startups into our programs across a wide range of categories, including therapeutics, diagnostics, assistive robotics, bio-manufacturing, remote care, and more. As the startups progress, SOSV joins their series seed, A and later rounds. That helps account for our strong showing in PitchBook leaderboards for active investors in categories such as healthcare devices & supplies, women\u2019s health, pharma and biotech.<\/p>\n\n\n\n

The 2023 SOSV Human Health 100<\/h2>\n\n\n\n